IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Tempus Partners with JW Pharmaceutical to Leverage Real-World Data and Biological Modeling for Enhanced R&D

Devyser Secures NMPA Approval for Devyser Compact, Expanding Genetic Testing Market in China

Qure.ai Partners with Roche’s Startup Creasphere to Enhance Healthcare Innovation in APAC

Six NHS Trusts to Deploy deepc’s AI Radiology Platform in Partnership with AI4VBC

Precision Medicine Program Marks Major Advancement in Kidney Transplant Care for Hereditary Kidney Disease Patients

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

Merck's KEYTRUDA® (pembrolizumab) Secures 30th European Commission Approval with Two New Indications for Gynecologic Cancers

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

Philips and Medtronic Partner to Advance Stroke Care and Awareness

Qatar Precision Health Institute Unveils Genomic Data and Announces New Research Initiatives

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

Thermo Fisher Partners with Telangana Government to Launch Bioprocess Design Centre in Hyderabad

Home
/
update
/
details

Telix Pharmaceuticals Spins Off Rhine Pharma to Expand Global Access to Radiopharmaceuticals

NextEdge Admin

23 Oct 2024

2 min 17 sec

Rhine Pharma,Heidelberg University Hospital,partnership,Radiopharmaceuticals

Telix Pharmaceuticals Limited has announced the spin-off of Rhine Pharma, a new venture focused on improving access to radiopharmaceuticals for cancer imaging and treatment. Rhine Pharma will leverage generator-produced isotopes technetium-99m (99mTc) and rhenium-188 (188Re) to offer innovative solutions, particularly in regions with limited infrastructure.

The company was formed through a collaboration between Telix and Heidelberg University Hospital (UKHD), resulting in RHN001, a PSMA-targeting small molecule that can be labeled with 99mTc for SPECT imaging or 188Re for radioligand therapy. Rhine Pharma will lead the clinical development of RHN001 through the RHINO Trial, a Phase I/IIa study assessing the safety and efficacy of both imaging and therapeutic versions of the compound in advanced prostate cancer patients.

Unlike radioisotopes such as lutetium-177 (177Lu) and actinium-225 (225Ac), which require centralized production, 99mTc and 188Re can be generated on-site, simplifying logistics and reducing costs. This flexibility makes Rhine Pharma's approach ideal for areas with dispersed populations or limited nuclear infrastructure.

Telix’s Managing Director, Christian Behrenbruch, emphasized the company’s commitment to increasing access to innovative treatments through Rhine Pharma. Meanwhile, the RHINO Trial will be conducted in collaboration with the Nuclear Medicine Research Infrastructure (NuMeRI) in South Africa, under the leadership of Professor Mike Sathekge.

The partnership aims to advance precision medicine and make radiopharmaceuticals more accessible worldwide. “Innovation and collaboration are key to delivering these benefits to all patients,” said Professor Sathekge.